Recombinant hepatitis B core antigen carrying preS1 epitopes induce immune response against chronic HBV infection

Vaccine

Volumn 22, Issue 3-4, 2004, Pages 439-446

  Chen, Xinchun ^a,b   Li, Meizhong ^a   Le, Xiaohua ^a   Ma, Weimin ^a   Zhou, Boping ^a  

^a SHENZHEN INSTITUTE OF INFORMATION TECHNOLOGY   (China)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

HBcAg; preS1; Therapeutic vaccine

Indexed keywords

CHIMERIC PROTEIN; EPITOPE; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; PRES1 PROTEIN; RECOMBINANT ANTIGEN; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS VECTOR;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CARBOXY TERMINAL SEQUENCE; CHIMERA; CONTROLLED STUDY; DRUG ANTIGENICITY; HEPATITIS B; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

EID: 0345528132     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2003.07.014     Document Type: Article

References (31)

1. Jung M.C., Gruner N., Zachoval R.et al. Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriers. Vaccine. 20:2002;3598-3612.
2. Yuen M.F., Lai C.L. Treatment of chronic hepatitis B. Lancet Infect. Dis. 1:2001;232-241.
3. Pol S., Driss F., Michel M.L., Nalpas B., Berthelot P., Brechot C. Specific vaccine therapy in chronic hepatitis infection. Lancet. 344:1994;342. [letter].
4. Pol S., Michel M.L., Brechot C. Immune therapy of hepatitis B virus chronic infection. Hepatology. 31:2000;548-549.
5. Couillin I., Pol S., Mancini M.et al. Specific vaccine therapy in chronic hepatitis B: induction of T-cell proliferative responses specific for envelope antigens. J. Infect. Dis. 180:1999;15-26.
6. Townsend K., Sallberg M., O'Dea J.et al. Characterization of CD8+ cytotoxic response after genetic immunization with retrovirus vectors expressing different forms of the hepatitis B core and e antigens. J. Virol. 71:1997;3365-3374.
7. Engler O.B., Dai W.J., Sette A.et al. Peptide vaccines against hepatitis B virus: from animal model to human studies. Mol. Immunol. 38:2001;457-465.
8. Heathcote J., Mchutchison J., Lee S.et al. A pilot study of C-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T-cell vaccine study group. Hepatology. 30:1999;531-536.
9. Bertoletti A., Chisari F.V., Penna A.et al. Definition of a minimal optimal cytotoxic T-cell epitope within the hepatitis B virus nucleocapsid protein. J. Virol. 67:1993;2376-2380.
10. Ferrari C., Penna A., Bertoletti A.et al. Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. J. Immunol. 145:1990;3442-3449.
11. Bertoletti A., Southwood S., Chesnut R.et al. Molecular features of the hepatitis b virus nucleocapsid T-cell epitopes 18-27: interaction with HLA and T-cell receptor. Hepatology. 26:1997;1027-1034.
12. Bocher W.O., Dekel B., Schwerin W.et al. Induction of strong hepatitis B virus specific T helper cell and cytotoxic T lymphocyte responses by therapeutic vaccination in the trimera mouse model of chronic HBV infection. Eur. J. Immunol. 31:2001;2071-2079.
13. Schodel F., Moriarty A.M., Peterson D.L.et al. The position of heterologous epitope inserted in hepatitis B virus core particles determines their immunogenicity. J. Virol. 66:1992;106-114.
14. Clarke B.E., Brown A.L., Grace K.G.et al. presentation and immunogenicity of viral epitopes on the surface of hybrid hepatitis B virus core particles produced in bacteria. J. Gen. Virol. 71:1990;1109-1117.
15. Jones C.D., Page M., Bacon A., Cahill E., Bentley M., Chatfield S.N. T-cell and antibody response characterization of a new recombinant preS1, preS2 and SHBs antigen-containing hepatitis B vaccine: demonstration of superior anti-SHBs antibody induction in responder mice. Vaccine. 17:1999;2528-2537.
16. Milich D.R., McLachlan A., Chisari F.V., Kent S.B., Thorton G.B. Immune response to the preS1 region of HBsAg: a preS1 specific T-cell response can bypass nonresponsiveness to the preS2 and S region of HBsAg. J. Immunol. 137:1986;315-322.
17. Prange R., Werr M., Birkner M., Hilfrich R., Streeck R.E. Properties of modified hepatitis B virus surface antigen particles carrying preS epitope. J. Gen. Virol. 76:1995;2131-2140.
18. Ferrari C., Penna A., Bertoletti A.et al. The preS1 antigen of HBV is highly immunogenic at T-cell level in man. J. Clin. Invest. 84:1989;1314-1319.
19. Milich D.R. T- and B-cell recognition of hepatitis B virus antigen. Immunol. Today. 9:1988;380-386.
20. Neurath A.R., Kent S.B., Strick N. Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus. Cell. 46:1986;429-436.
21. Paran N., Geiger B., Shaul Y. HBV infection of cell culture: evidence for multivalent and cooperative attachment. EMBO J. 16:2001;4443-4453.
22. Neurath A.R., Seto B., Strick N. Antibody to synthetic peptides from the preS1 region of the hepatitis B virus envelop (env) protein are virus-neutralizing and protective. Vaccine. 7:1989;234-236.
23. Milich D.R., Schodel F., Hughes J.L., Jones J.E., Peterson D.L. The hepatitis B virus core and e antigens elicit different Th cell subsets: antigen structure can affect Th cell phenotype. J. Virol. 71:1997;2192-2201.
24. Milich D.R. Immune response to hepatitis B virus: infection, animal model, vaccine. Viral Hepat. Rev. 3:1997;63-103.
25. Hatton T., Zhou S., Standring D.N. RNA- and DNA-binding activities in hepatitis B virus capsid protein: a model for their roles in viral replication. J. Virol. 66:1992;5232-5241.
26. Kratz P.A., Bottcher B., Nassal M. Native display of complete foreign protein domains on the surface of hepatitis B virus capsids. Proc. Natl. Acad. Sci. U.S.A. 96:1999;1915-1920.
27. Birnbaum F., Nassal M. Hepatitis B virus nucleotide assembly: primary structure requirements in the core protein. J. Virol. 64:1990;3319-3330.
28. Hui J., Li G., Kong Y., Wang Y. Expression and characterization of chimeric hepatitis B surface antigen particles carrying preS epitope. J. Biotechnol. 72:1999;49-59.
29. Hezel F. Th1 and Th2 cells in the cure and pathogenesis of infectious diseases. Curr. Opin. Infect. Dis. 8:1995;151-155.
30. Malanchere-Bres E., Payette P.J., Mancini M., Tiollais P., Davis H.L., Michel M.L. CpG oligodexynucleotides with hepatitis B surface antigen (HBsAg) for vaccination in HBsAg-transgenic mice. J. Virol. 75:2001;6482-6491.
31. Reidl P., Stober D., Oehninger C.et al. Priming Th1 immunity to viral core particles is facilitated by trace amounts of RNA bound to its arginine-rich domain. J. Immunol. 168:2002;4951-4959.